Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease
Identifieur interne : 002A11 ( Ncbi/Merge ); précédent : 002A10; suivant : 002A12Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease
Auteurs : Rodger J. Elble ; Oksana Suchowersky [Canada] ; Stephanie Shaftman ; William J. Weiner ; Peng Huang ; Barbara TilleySource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2010.
English descriptors
- KwdEn :
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Neuroprotective Agents (therapeutic use), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Randomized Controlled Trials as Topic, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome, Ubiquinone (therapeutic use).
- MESH :
- chemical , therapeutic use : Neuroprotective Agents, Ubiquinone.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Aged, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Randomized Controlled Trials as Topic, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome.
Abstract
We explored the hypotheses that an investigator’s belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of Parkinson patients with the Unified Parkinson Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q10 and GPI-1485. We found the investigators’ level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.
Url:
DOI: 10.1002/mds.22997
PubMed: 20131372
PubMed Central: 2891220
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000082
- to stream Pmc, to step Curation: 000082
- to stream Pmc, to step Checkpoint: 000338
- to stream PubMed, to step Corpus: 001991
- to stream PubMed, to step Curation: 001991
- to stream PubMed, to step Checkpoint: 001836
Links to Exploration step
PMC:2891220Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20131372</idno><idno type="pmc">2891220</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891220</idno><idno type="RBID">PMC:2891220</idno><idno type="doi">10.1002/mds.22997</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000082</idno><idno type="wicri:Area/Pmc/Curation">000082</idno><idno type="wicri:Area/Pmc/Checkpoint">000338</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">001991</idno><idno type="wicri:Area/PubMed/Curation">001991</idno><idno type="wicri:Area/PubMed/Checkpoint">001836</idno><idno type="wicri:Area/Ncbi/Merge">002A11</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Ubiquinone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">We explored the hypotheses that an investigator’s belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of Parkinson patients with the Unified Parkinson Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q<sub>10</sub> and GPI-1485. We found the investigators’ level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</p></div></front></TEI><double pmid="20131372"><pmc><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">20131372</idno><idno type="pmc">2891220</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2891220</idno><idno type="RBID">PMC:2891220</idno><idno type="doi">10.1002/mds.22997</idno><date when="2010">2010</date><idno type="wicri:Area/Pmc/Corpus">000082</idno><idno type="wicri:Area/Pmc/Curation">000082</idno><idno type="wicri:Area/Pmc/Checkpoint">000338</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J." last="Elble">Rodger J. Elble</name><affiliation><nlm:aff id="A1"> Department of Neurology, Southern Illinois University School of Medicine</nlm:aff><wicri:noCountry code="subfield">Southern Illinois University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name><affiliation wicri:level="4"><nlm:aff id="A2"> Departments of Medical Genetics and Clinical Neurosciences, University of Calgary</nlm:aff><country>Canada</country><placeName><settlement type="city">Calgary</settlement><region type="state">Alberta</region></placeName><orgName type="university">Université de Calgary</orgName></affiliation></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name><affiliation><nlm:aff id="A3"> Department of Biostatistics, Bioinformatics and Epidemiology, Medical University of South Carolina</nlm:aff><wicri:noCountry code="subfield">Medical University of South Carolina</wicri:noCountry></affiliation></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J." last="Weiner">William J. Weiner</name><affiliation><nlm:aff id="A4"> Department of Neurology, University of Maryland School of Medicine</nlm:aff><wicri:noCountry code="subfield">University of Maryland School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name><affiliation><nlm:aff id="A5"> Department of Oncology, Johns Hopkins University</nlm:aff><wicri:noCountry code="subfield">Johns Hopkins University</wicri:noCountry></affiliation></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name><affiliation><nlm:aff id="A6"> University of Texas Health Science Center School of Public Health at Houston</nlm:aff></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><date when="2010">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">We explored the hypotheses that an investigator’s belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of Parkinson patients with the Unified Parkinson Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q<sub>10</sub> and GPI-1485. We found the investigators’ level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</p></div></front></TEI></pmc><pubmed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease.</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J" last="Elble">Rodger J. Elble</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA. relble@siumed.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J" last="Weiner">William J. Weiner</name></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="doi">10.1002/mds.22997</idno><idno type="RBID">pubmed:20131372</idno><idno type="pmid">20131372</idno><idno type="wicri:Area/PubMed/Corpus">001991</idno><idno type="wicri:Area/PubMed/Curation">001991</idno><idno type="wicri:Area/PubMed/Checkpoint">001836</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease.</title><author><name sortKey="Elble, Rodger J" sort="Elble, Rodger J" uniqKey="Elble R" first="Rodger J" last="Elble">Rodger J. Elble</name><affiliation wicri:level="2"><nlm:affiliation>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois, USA. relble@siumed.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Southern Illinois University School of Medicine, Springfield, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Suchowersky, Oksana" sort="Suchowersky, Oksana" uniqKey="Suchowersky O" first="Oksana" last="Suchowersky">Oksana Suchowersky</name></author><author><name sortKey="Shaftman, Stephanie" sort="Shaftman, Stephanie" uniqKey="Shaftman S" first="Stephanie" last="Shaftman">Stephanie Shaftman</name></author><author><name sortKey="Weiner, William J" sort="Weiner, William J" uniqKey="Weiner W" first="William J" last="Weiner">William J. Weiner</name></author><author><name sortKey="Huang, Peng" sort="Huang, Peng" uniqKey="Huang P" first="Peng" last="Huang">Peng Huang</name></author><author><name sortKey="Tilley, Barbara" sort="Tilley, Barbara" uniqKey="Tilley B" first="Barbara" last="Tilley">Barbara Tilley</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Neuroprotective Agents (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term><term>Ubiquinone (therapeutic use)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Neuroprotective Agents</term><term>Ubiquinone</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Dose-Response Relationship, Drug</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Randomized Controlled Trials as Topic</term><term>Severity of Illness Index</term><term>Statistics, Nonparametric</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We explored the hypotheses that an investigator's belief in a putative neuroprotective agent might influence the timing of symptomatic intervention and the assessment of signs and symptoms of patients with Parkinson's disease with the Unified Parkinson's Disease Rating Scale (UPDRS). These hypotheses were tested with Cox and general linear modeling, using data from a previously published double-blind placebo-controlled futility trial of coenzyme Q(10) and GPI-1485. We found the investigators' level of confidence in these agents had no effect on the time to symptomatic therapy or on the change in UPDRS during 12 months of treatment.</div></front></TEI></pubmed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A11 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 002A11 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= PMC:2891220
|texte= Impact of belief in neuroprotection on therapeutic intervention in Parkinson disease
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:20131372" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |